← Back to libraryEntry · LZH-016

lyophilized

KED · Vascular research

Vesugen

Vascular matrix bioregulatory tripeptide

Technical datasheetLZH-016

Code: KED
Half-life: Short plasma; transcriptional effects persist
Research route: SC / sublingual (research)
Molecular targets: Endothelial gene expression modulation
Discovery / disclosure: Khavinson group, 2000s
Target purity: ≥ 98%
Recommended storage: −20°C, light protected. 2 to 8°C after reconstitution.

Aliases

KED tripeptide

Appearance

White lyophilized powder

Solubility

Water soluble

Sequence

Lys-Glu-Asp

Analysts reviewing the HPLC chromatogram for the current batch — FIG. 201Analytical Lab
Identity, purity and main-peak area are checked by reversed-phase HPLC against an in-house reference standard for this sequence. The chromatogram you see on the certificate of analysis is generated at this exact bench, by the analysts who release the batch.

Technician monitoring a stainless steel reactor during scale-up — FIG. 202Scale-up Operations
When a sequence moves from milligram research lots to multi-gram research supply, the same chemistry is transferred onto jacketed stainless reactors. Temperature, agitation and reagent equivalents are logged in real time so that the larger batch matches the analytical fingerprint of the small one.

Overview

Vesugen is the Lys-Glu-Asp (KED) tripeptide within the Khavinson bioregulator family, focused on vascular wall and endothelial cell research.

Pharmacology and mechanism

Modulates endothelial gene expression, linked to transcription of vascular homeostasis and endothelial function factors.

Research areas

R.01

Vascular matrix bioregulatory tripeptide

Tool molecule in vascular aging, endothelial function and vascular matrix biology studies.

Structural notes

Tripeptide Lys-Glu-Asp.

Sequence

Lys-Glu-Asp

For research use only. Not medical advice. Not for diagnosis or treatment.

Related molecules

Dual receptor agonist

Open →

GIP / GLP-1 / GCG

Retatrutide

Triple receptor agonist

Open →

Elamipretide639.8 Da

SS-31

Mitochondrial targeting

CJC-1295 + Ipamorelin

GH pulse combination

Open →